Head to head
Boston Scientific vs Abbott Laboratories
Side-by-side on the measures that matter, with a plain-English read. Full detail: BSX · ABT
BSX
Boston Scientific
41.58-1.45%
1-year price shape — -57% over the period
Quant Rating E · 2/100
vs
ABT
Abbott Laboratories
98.73+0.58%
1-year price shape — -24% over the period
Quant Rating E · 15/100
1-year performance, rebased to 100
Abbott Laboratories edges it on the scoreable measures. Abbott Laboratories has the highest Quant Rating (15); Abbott Laboratories has done best over the past year (-24%); Abbott Laboratories pays the highest dividend yield.
| BSX | ABT | |
|---|---|---|
| Snapshot | ||
| Sector | -- | Medical Devices |
| Last price | 41.58 | 98.73 |
| Change today | -1.45% | +0.58% |
| 1-year return | -56.6% | -24.1% |
| Market cap | $60.26B | $170.84B |
| 52-week range | 41.50 – 105.65 | 81.39 – 130.33 |
| Valuation | ||
| P/E (TTM) | 16.83 | 31.95 |
| P/E percentile, own 5-yr range | 0th | 62nd |
| P/B | 2.42 | 3.34 |
| Dividend yield | 0.00% | 2.47% |
| Profitability & growth | ||
| EPS (TTM) | 1.94 | 3.72 |
| Net profit (TTM) | $2.81B | $6.44B |
| Revenue (TTM) | $21.00B | $46.59B |
| Revenue growth (YoY) | +7.5% | +13.0% |
| Gross margin | 69.9% | 56.6% |
| Operating margin | 21.0% | 15.8% |
| Net margin | 17.5% | 11.6% |
| Free cash flow (TTM) | $1.81B | $7.82B |
| Ownership & sentiment | ||
| Institutional ownership | 94.0% | 81.2% |
| Insider activity (12mo) | 38 buy / 11 sell | 36 buy / 12 sell |
| Short interest (% of float) | 3.2% | 1.1% |
| Analyst consensus | 86% buy / 14% hold (21) | 100% buy (14) |
| Analyst price target | $59 (+41%) | $125 (+26%) |
| StockVane view | ||
| StockVane Quant Rating | E (2) | E (15) |
| Company | ||
| Employees | 59,000 | 115,000 |
| Founded | 1979 | 1888 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.